Ledertrexato

Methotrexate, the active ingredient in Ledertrexato, is an antimetabolite presented as an oral tablet for oral use. It interferes with folate metabolism and is indicated for the management of autoimmune diseases such as rheumatoid arthritis and psoriasis, as well as for several hematologic and solid‑tumor cancers in both adult and pediatric populations.

GNH USA supplies Ledertrexato as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, ensuring quality and regulatory compliance across EU and global markets.

Methotrexate is used in several autoimmune and oncologic disease pathways, providing disease control and symptom relief.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin lesion severity and plaque formation. - Acute lymphoblastic leukemia: induces remission by targeting rapidly dividing lymphoblasts. - Non‑Hodgkin lymphoma: impairs tumor cell proliferation and promotes apoptosis. - Gestational trophoblastic disease: eradicates trophoblastic tissue and prevents disease recurrence.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting: gastrointestinal discomfort occurring early in therapy. - Stomatitis: inflammation or ulceration of the oral mucosa. - Fatigue: persistent tiredness not relieved by rest. - Elevated liver enzymes: mild transaminase increase detectable on blood tests.

Serious or Rare Side Effects: - Bone marrow suppression: pancytopenia leading to infection, bleeding or anemia. - Pulmonary toxicity: interstitial pneumonitis presenting with cough and dyspnea. - Severe hepatotoxicity: fibrosis or cirrhosis with prolonged use.

When prescribing methotrexate, clinicians should observe several safety measures to minimize risks.

- Pregnancy: contraindicated (Category X) due to teratogenic potential. - Renal function: assess creatinine clearance; dose adjustment may be required. - Hepatic disease: monitor liver function tests regularly. - Concomitant NSAIDs: avoid or use with caution as they may increase toxicity. - Immunosuppression: monitor for signs of infection and advise patients to report fevers promptly. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Methotrexate interacts with several medicines that can alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Live vaccines: may cause severe infection due to immunosuppression. - High‑dose aspirin or NSAIDs: increase methotrexate plasma levels and risk of toxicity. - Proton pump inhibitors (omeprazole, esomeprazole): may reduce renal clearance and raise serum concentrations.

Moderate Interactions (Monitor Closely): - Sulfonamide antibiotics (trimethoprim‑sulfamethoxazole): can enhance myelosuppression. - Azathioprine or other immunosuppressants: additive bone marrow suppression. - Penicillins (amoxicillin): may modestly increase methotrexate levels.